Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Post-traumatic Seizures With Levetiracetam (TRACK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00566046
Recruitment Status : Terminated (Sponsor decision because of to small enrollment)
First Posted : November 30, 2007
Last Update Posted : June 21, 2012
Sponsor:
Collaborator:
UCB Pharma
Information provided by (Responsible Party):
Rennes University Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Post-traumatic seizures can appear frequently after a severe traumatic brain injury. Two types of seizures are usually identified: early seizures during the week following the trauma and late epilepsy afterward. Several antiepileptic drugs are usually used to prevent early seizures but no treatment has demonstrated any preventive effect against late epilepsy. Levetiracetam is an antiepileptic drug usually used for the treatment of epileptic patients and has pharmacologic properties that could also be interesting for the prevention of post-traumatic epilepsy.

Condition or disease Intervention/treatment Phase
Epilepsy, Post-Traumatic Drug: Levetiracetam Drug: Placebo Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Prospective, Randomized, Double-blind Study Assessing the Effects of Levetiracetam Compared to Placebo in the Prevention of Early Epileptic Seizures and Late Epilepsy in Patients With Severe Traumatic Brain Injury
Study Start Date : November 2007
Actual Primary Completion Date : December 2009
Actual Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy Seizures

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Levetiracetam Drug: Levetiracetam
1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
Other Name: Keppra
Placebo Comparator: Placebo Drug: Placebo
1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Time to early epileptic seizures (<= 8 days) and late epilepsy (from day 9 to 1 year) in patients with severe traumatic brain injury [ Time Frame: one year ]

Secondary Outcome Measures :
  1. Rate of early seizures and of late epilepsy; treatment effects according to the patient's severity, the TDM US Traumatic Coma Data Bank, and the number of regions traumatized; safety of Levetiracetam [ Time Frame: One year ]
  2. Global prognosis (Glasgow Outcome Scale) [ Time Frame: 3 months, 6 months and 1 year ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age >= 18 years old

  2. Patient with severe brain injury defined as follow:

    • Initial Glasgow Coma score (assessed on the scene of the accident) <= 8 related to the brain injury
    • Stage 2 to 4 on the TDM US TCDB classification
  3. Initial brain CT scan performed within 48 hours after hospital admission
  4. Either a male or a nonpregnant, non-lactating female who is using adequate contraceptive method (a urine laboratory pregnancy test must be negative at baseline)
  5. Written informed consent from the patient's next-of-kin. If no relative is present as the time of inclusion, the patients will be included according to the emergency procedure

Exclusion Criteria:

  1. Isolated extradural hematoma
  2. Medical decision to limit patient's care (terminal stage of a cancer, hematological malignancies, HIV, etc.)
  3. Current participation in an other protocol or within one month before study entry
  4. Previous treatment with Levetiracetam
  5. Patient's follow-up judged to be difficult by the investigator
  6. Known allergy to either Levetiracetam or products derived from pyrrolidone or one of its excipients
  7. Epileptic patient treated or not (except patients treated with benzodiazepines who can be included in this protocol)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00566046


Locations
Layout table for location information
France
Neurologie - CHU Angers
Angers, France
Neurology - CHU Bordeaux
Bordeaux, France
Neurologie - CHU Caen
Caen, France
Neurochirurgie-CHU Grenoble
Grenoble, France
Neurology - CHU Rennes
Grenoble, France
Neurophysiologie Clinique - CHU Lille
Lille, France
Neurophysiologie clinique - CHU Lyon (Hôpital neurologique)
Lyon, France
Beurophysiologie clinique - CHU Marseille
Marseille, France
Epileptologie - CHU Montpellier
Montpellier, France
Neurologie - CHU Nancy
Nancy, France
Neurochirurgie-Paris Saint Anne
Paris, France, 75674
Neurologie - CHU Rennes
Rennes, France, 35000
Explorations Fonctionnelles Neurologiques - CHU Nantes
Rennes, France
Neurologie - CHU Rouen
Rouen, France
Neurologie - CHU Tours Hopital Trousseau
Tours, France
Sponsors and Collaborators
Rennes University Hospital
UCB Pharma
Investigators
Layout table for investigator information
Principal Investigator: Arnaud Biraben, MD Rennes University Hospital
Study Chair: Bruno Laviolle, MD Rennes University Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Rennes University Hospital
ClinicalTrials.gov Identifier: NCT00566046    
Other Study ID Numbers: EudraCT: 2006-006518-13
CIC0203/60 ( Other Identifier: Rennes University Hospital )
LOC/06-06 ( Other Identifier: Rennes University Hospital )
First Posted: November 30, 2007    Key Record Dates
Last Update Posted: June 21, 2012
Last Verified: June 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Seizures
Epilepsy, Post-Traumatic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
 Brain Injuries
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries
Levetiracetam
Anticonvulsants
Nootropic Agents